title: The TGF-β pathway as an emerging target for Chagas disease therapy.
abstract: Transforming growth factor-β (TGF-β) influences the development of myocardiopathy in Chagas disease through regulation of (i) parasite invasion of heart cells, (ii) an intracellular parasite cycle, (iii) inflammation and immune response, (iv) heart fibrosis and remodeling, and (v) gap junction modulation and heart conduction. In this review, we discuss the rationale for developing TGF-β signaling-interfering therapies as adjuvant approaches for the management of the cardiac alterations of Chagas disease-affected patients.
authors.affiliation: Laboratório de Inovações em Terapias, Ensino e Bioprodutos, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil.
authors.forename: T C
authors.initials: TC
authors.lastname: Araújo-Jorge
authors.forename: M C
authors.initials: MC
authors.lastname: Waghabi
authors.forename: S
authors.initials: S
authors.lastname: Bailly
authors.forename: J-J
authors.initials: JJ
authors.lastname: Feige
mesh_terms: D000818:Animals; D002598:Chagas Cardiomyopathy / Q000188:drug therapy* / Q000469:parasitology / Q000503:physiopathology; D014355:Chagas Disease / Q000188:drug therapy* / Q000469:parasitology / Q000503:physiopathology; D015195:Drug Design; D017629:Gap Junctions / Q000469:parasitology; D006329:Heart Conduction System / Q000469:parasitology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000469:parasitology; D015398:Signal Transduction / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000378:metabolism*; D014349:Trypanosoma cruzi / Q000302:isolation & purification
chemical_list: D016212:Transforming Growth Factor beta